Want to see AU:CLV full AI Analyst Report?
Top Page
Clover Corporation Limited
(Sydney:CLV)
Select Model
Select Model
Rating:81Outperform
Price Target:
AU$1.00
▲(9.89% Upside)
Action:Reiterated
Date:09/29/26
The score is driven primarily by strong fundamentals—rising profitability and a very low-debt balance sheet—plus a positive earnings outlook from the latest call. The main constraint is cash-flow consistency due to elevated inventory and working-capital requirements, while technicals are supportive and valuation appears reasonable rather than deeply discounted.
Positive Factors
Profitable revenue growth and margin expansion
Strong revenue growth combined with higher gross margins and substantial EBITDA and NPAT gains indicates meaningful operating leverage. If product mix, innovation and vertical integration continue supporting profitability, Clover can strengthen earnings capacity over the next several reporting periods.
Negative Factors
Working-capital intensity weakens cash conversion
Higher inventory and working-capital requirements are absorbing cash even as reported earnings improve. The need to purchase, test, process and hold more oil and finished goods may keep cash conversion volatile, limiting internally funded investment and reducing the quality of near-term earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitable revenue growth and margin expansion
Strong revenue growth combined with higher gross margins and substantial EBITDA and NPAT gains indicates meaningful operating leverage. If product mix, innovation and vertical integration continue supporting profitability, Clover can strengthen earnings capacity over the next several reporting periods.
Read all positive factors
Clover Corporation Limited (CLV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$164.49M
Dividend Yield2.46%
Average Volume (3M)251.69K
Price to Earnings (P/E)15.9
Beta (1Y)0.16
Revenue Growth13.26%
EPS Growth49.05%
CountryAU
Employees81
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.06
Shares Outstanding166,999,340
10 Day Avg. Volume312,365
30 Day Avg. Volume251,695
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.06
Price to Sales (P/S)1.65
P/FCF Ratio48.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$115.05M
Clover Corporation Limited Business Overview & Revenue Model
Company Description
Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products ...
How the Company Makes Money
Clover Corporation Limited makes money primarily by supplying encapsulated oil powders and related functional ingredient products to customers (typically manufacturers and brand owners) that incorporate these ingredients into finished nutrition an...
Clover Corporation Limited Earnings Call Summary
Earnings Call Date:Sep 22, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 16, 2027
Earnings Call Sentiment Positive
The call was strongly positive overall, with record revenue, improved gross margin, substantial EBITDA and NPAT growth, debt repayment, expanding ARA demand and a positive first-half FY 2027 outlook. The main challenges were higher inventory and working capital requirements, an AUD 1.1 million FX translation loss, increased investment costs, U.S. market-entry execution and limited CholineXcel manufacturing capacity. Highlights significantly outweighed the lowlights.Positive Updates
Record Revenue and Gross Margin
FY 2026 revenue reached AUD 97.4 million, ahead of guidance of AUD 92 million to AUD 96 million and up 13% from AUD 86 million in the prior year. Average gross margin was 35.5%, representing a 4% improvement, supported by innovation, increased product mix and vertical integration.
Negative Updates
Higher Net Working Capital and Inventory
Net working capital increased to AUD 49.8 million, up AUD 7.5 million year on year. Inventory increased by AUD 19.8 million, with the balance approximately 50% raw materials and 50% finished goods, to support higher ARA and fish oil demand and the company's longer supply chain.
Read all updates
Q4-2026 Updates
Positive
Negative
Record Revenue and Gross Margin
FY 2026 revenue reached AUD 97.4 million, ahead of guidance of AUD 92 million to AUD 96 million and up 13% from AUD 86 million in the prior year. Average gross margin was 35.5%, representing a 4% improvement, supported by innovation, increased product mix and vertical integration.
Read all positive updates
Company Guidance
For FY 2027, the board expects revenue for the first half of FY 2027 to be ahead of the prior corresponding period, ARA’s second half to continue into the first half of this year, and the second biggest customer to increase, with Peter Davey saying it could return or surpass its FY 2025 level; CholineXcel will be released in limited volume, with initial customer orders expected, followed by scaled-up manufacturing, while a limited release is expected in FY 2027 and infant-formula sales could be late 2028 unless capacity is secured quickly. The company expects additional U.S. nutraceutical-market costs over the next two to three years and will gradually increase its expense, while Premneo is probably two years off.Clover Corporation Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
62
Positive
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 97.41M | 86.00M | 62.21M | 79.88M | 70.66M |
| Gross Profit | 33.97M | 26.17M | 16.86M | 23.74M | 21.66M |
| EBITDA | 17.78M | 12.24M | 3.98M | 10.01M | 11.66M |
| Net Income | 10.46M | 7.01M | 1.51M | 6.21M | 7.13M |
Balance Sheet | |||||
| Total Assets | 97.76M | 86.80M | 84.39M | 86.20M | 90.77M |
| Cash, Cash Equivalents and Short-Term Investments | 7.22M | 8.68M | 12.26M | 9.44M | 10.11M |
| Total Debt | 1.07M | 2.42M | 10.39M | 11.71M | 12.08M |
| Total Liabilities | 19.80M | 14.57M | 17.32M | 19.05M | 27.73M |
| Stockholders Equity | 77.96M | 72.23M | 67.07M | 67.15M | 63.04M |
Cash Flow | |||||
| Free Cash Flow | 3.32M | 6.95M | 6.13M | 5.10M | 4.51M |
| Operating Cash Flow | 4.39M | 8.29M | 8.45M | 6.74M | 5.93M |
| Investing Cash Flow | -461.00K | -1.34M | -2.97M | -2.53M | -1.43M |
| Financing Cash Flow | -5.40M | -10.52M | -2.66M | -4.88M | -3.49M |
Clover Corporation Limited Technical Analysis
Neutral
0.91
Price Trends
0.95
Positive
0.91
Positive
0.88
Positive
Market Momentum
0.02
Positive
48.51
Neutral
35.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CLV, the sentiment is Neutral. The current price of 0.91 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 0.95, and above the 200-day MA of 0.88, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.51 is Neutral, neither overbought nor oversold. The STOCH value of 35.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CLV.
Clover Corporation Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | AU$224.26M | 23.09 | 56.29% | ― | 160.87% | 188.14% | |
81 Outperform | AU$164.49M | 15.89 | 13.83% | 2.46% | 13.26% | 49.05% | |
63 Neutral | AU$1.91B | 34.96 | 5.46% | 2.32% | 6.66% | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | AU$33.25M | -0.53 | 13.40% | 1.21% | 8.82% | 55.22% | |
46 Neutral | AU$78.77M | -17.12 | -11.08% | ― | 9.08% | -183.87% | |
39 Underperform | AU$18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:CLV
Clover Corporation Limited
0.99
0.37
60.16%
AU:NOU
Noumi Limited
0.12
-0.01
-7.69%
AU:BGA
Bega Cheese Limited
6.24
0.91
17.16%
AU:BLS
Bioxyne Limited
0.95
0.54
131.71%
AU:BUB
Bubs Australia Ltd.
0.09
-0.06
-41.33%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-5.00%
Clover Corporation Limited Corporate Events
Clover Corporation Sets AGM Date and Director Nomination Deadline
Sep 22, 2026
Clover Corporation Limited, an ASX-listed Australian specialist in microencapsulated nutritional oils, supplies technology that enables tuna, fish, algal and fungal oils to be incorporated into infant formula, foods and beverages. Its proprietary ...
Clover Corporation Outlines Leadership and Governance in 2026 Annual Report
Sep 22, 2026
Clover Corporation has released its annual report for the year ended 31 July 2026, outlining its corporate structure and governance framework. The document highlights board changes, including the retirement of non-executive director Graeme Billing...
Clover Corporation Declares Interim Dividend for Half-Year to July 2026
Sep 22, 2026
Clover Corporation Limited has declared an interim dividend of AUD 0.0125 per ordinary fully paid share, relating to the six-month period ended 31 July 2026. The shares will trade ex-dividend on 20 October 2026, with a record date of 21 October 20...
Clover Corporation Files Appendix 4G, Detailing Governance Compliance With ASX Standards
Sep 22, 2026
Clover Corporation has lodged its Appendix 4G with the ASX alongside its annual report, confirming that its corporate governance statement for the year ended 31 July 2026 is included in the report on pages 30 to 40 and has been approved by the boa...
Clover Corporation sets date for FY26 results and investor webinar
Sep 8, 2026
Clover Corporation Limited, a specialist in microencapsulated nutritional oils for the global food and infant formula industries, will publish its FY26 financial results before the market opens on 23 September 2026. The Australian-listed company a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.